Assenagon Asset Management S.A. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 159.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,337,717 shares of the biopharmaceutical company’s stock after buying an additional 1,437,842 shares during the period. Assenagon Asset Management S.A. owned 0.19% of Gilead Sciences worth $195,994,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of GILD. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after acquiring an additional 2,910,147 shares during the period. Swedbank AB bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $134,489,000. International Assets Investment Management LLC increased its position in Gilead Sciences by 8,238.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after purchasing an additional 1,622,806 shares in the last quarter. Capital Research Global Investors increased its position in Gilead Sciences by 2.7% during the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock worth $4,486,296,000 after purchasing an additional 1,589,240 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in Gilead Sciences by 24.7% during the 2nd quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock worth $541,310,000 after purchasing an additional 1,564,792 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Read Our Latest Analysis on Gilead Sciences
Gilead Sciences Stock Performance
NASDAQ GILD traded up $1.63 during trading hours on Thursday, reaching $88.86. 3,091,947 shares of the company were exchanged, compared to its average volume of 7,030,024. The business’s 50 day simple moving average is $81.87 and its 200-day simple moving average is $73.17. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $89.21. The stock has a market capitalization of $110.71 billion, a P/E ratio of 247.53, a P/E/G ratio of 2.98 and a beta of 0.18.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.47%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s payout ratio is currently 855.56%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- The Significance of Brokerage Rankings in Stock Selection
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What is a Death Cross in Stocks?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.